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ABSTRACT 
Breast cancer-related lymphedema (BCRL) is one of the most common complications of breast cancer treatments, 
which may be exacerbated by obesity. Dysbiosis may negatively impact the management of obesity and 
lymphedema by increasing inflammation. The objective of this study was to assess the effects of supplementation 
with synbiotics on inflammatory markers, serum leptin concentration and edema volume in overweight and obese 
BCRL women following a low-calorie diet (LCD). In a randomized double-blind controlled clinical trial, 88 breast 
cancer survivors with lymphedema were supplemented once a day for 10 weeks with either a synbiotic or a placebo 
capsule. Both groups were under a low-calorie diet (LCD). At the end of the study, synbiotic supplementation 
resulted in a significant reduction in leptin (P=0.003) and TNF-α (P=0.039) between the study groups. Besides, 
edema volume was significantly reduced within the synbiotic group after the intervention. We did not observe any 
significant effects of the synbiotic supplementation in hs-CRP, and IL-1β between the study groups (P=0.550, 
P=0.118 respectively). Conclusively, synbiotic supplementation along with an LCD program in breast cancer sur-
vivors with lymphedema had beneficial effects on the concentration of serum inflammatory markers and edema 
volume.  
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INTRODUCTION 
Breast cancer (BC) is an important health 
concern in women worldwide (Coughlin and 
Ekwueme, 2009). Due to advances in cancer 
treatment and early detection, the five-year 
relative survival rate for females diagnosed 
with BC has increased to 89.7 % (American 
Cancer Society, 2018). However, many of 
these patients face chronic complications of 
BC treatments, such as lymphedema 
(Erickson et al., 2001). Lymphedema is the 
most prevalent and distressing symptom for 
patients with breast cancer after surgery 
and/or radiation (Wanchai et al., 2016).  
Breast cancer survivors may experience 
lymphedema complications for months or 
years after cancer treatment (Norman et al., 
2009). Breast cancer-related lymphedema 
(BCRL) incidence has been reported to be 
21.4 % (DiSipio et al., 2013) and is character-
ized by swelling, heaviness, pain, limb use 
limitation, and decreased quality of life 
(Hormes et al., 2010; Dayan et al., 2018). The 
lymphatic system is critically important in 
maintaining tissue fluid homeostasis and reg-
ulating the inflammatory response by improv-
ing drainage of extravasated fluid, thus reduc-
ing edema formation and levels of pro-inflam-
matory mediators include tumor necrosis fac-
tor-α (TNF-α) (Schwager and Detmar, 2019).  
Lymphatic injury due to cancer treatments 
leads to the disruption of lymph flow. Lym-
phatic fluid stasis may cause increased in-
flammatory mediators such as TNF-α, fat 
deposition and progressive fibrosis (Gouso-
poulos et al., 2016, Tashiro et al., 2017). Be-
side, TNF-α plays the main role in inflamma-
tion-induced lymphatic contractile dysfunc-
tion (Chen et al., 2017). Studies have impli-
cated that chronic inflammation is a hallmark 
in the pathophysiology of lymphedema (Ly et 
al., 2017; Rockson et al., 2018). 
Many studies indicated that obesity and 
also overweight may predispose women to 
lymphedema and may affect the response to 
treatment (DiSipio et al., 2013; Ly et al., 
2017; Helyer et al., 2010; Hespe et al., 2017; 
Rockson et al., 2018). Moreover, obesity has 
a positive correlation with lymphedema se-
verity (Ridner et al., 2011; Helyer et al., 
2010). In contrast, weight loss programs have 
effectively improved the treatment of BCRL 
(Shaw et al., 2007a, b). An increase in serum 
leptin concentration has been reported in 
obese patients (Minocci et al., 2000; Van 
Dielen et al., 2001). Leptin enhances the ex-
pression of pro-inflammatory cytokines, such 
as TNF-α (Bulló et al., 2003). Since obesity is 
a major risk factor for lymphedema (Vignes 
et al., 2007; Mehrara and Greene, 2014), the 
increased level of leptin in overweight and 
obese patients, can exacerbate inflammation 
and increase the edema severity (Ly et al., 
2017). Anti-inflammatory and anti-fibrotic 
agents seem to be two key factors in prevent-
ing the progression of this disorder 
(Schaverien and Aldrich, 2018; Hespe et al., 
2017; Rockson et al., 2018).  
Dysbiosis or gut microflora alteration is 
not uncommon among overweight and obese 
individuals (Brown et al., 2012), which may 
cause systemic inflammation (Le Chatelier et 
al., 2013; Verdam et al., 2013). Probiotics are 
living and non-pathogenic bacteria with help-
ful effects for improving or maintaining the 
microbiome which can modify the microflora 
(Alard et al., 2016; Wischmeyer et al., 2016). 
Synbiotics refer to food ingredients or dietary 
supplements combining probiotics and prebi-
otics, non-digestible fiber compounds that 
stimulate the growth of beneficial bacteria, in 
the form of synergism (Pandey et al., 2015).  
Further, probiotics may contribute to im-
proved homeostasis and decreased side ef-
fects related to anti-cancer therapies (Mego et 
al., 2013). Moreover, it has been shown that 
decreased inflammation may occur by reduc-
ing the production of pro-inflammatory cyto-
kines, including interleukin‐1 (IL-1) and 
TNF-α (McLoughlin et al., 2017). On the 
other hand, the intestinal microbiome dysbio-
sis has been shown to affect the development 
of lymphedema through complicated biologi-
cal mechanisms including downregulation of 
pro-inflammatory cytokines such as TNF-α 
(Amdekar et al., 2012; Archer et al., 2015; 
Solanki et al., 2015). 
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We are aware of no study that has exam-
ined the effect of synbiotic supplementation 
on inflammatory profiles and edema volume 
in BCRL. The current study was therefore 
performed to investigate the effects of synbi-
otics on the inflammation status and edema 
volume of breast cancer survivors with 
lymphedema following a low-calorie diet. 
The result of this research may provide new 
strategies for lymphedema management. 
 
MATERIALS AND METHODS 
Study design  
Women with BC related lymphedema 
who were treated by complex decongestive 
therapy (CDT) were recruited in this random-
ized double-blind controlled clinical trial. 
Lymphedema therapy was carried out in two 
phases, including an intensive phase that is 
performed in the clinic and a maintenance 
phase which is achieved by the patient and 
family at home to stabilize edema reduction. 
This study was conducted in the maintenance 
phase to assess the effect of the interventions 
on changing limb volume. 
Our study was approved by the Ethics 
Committee of Iran University of Medical Sci-
ences and followed the Declaration of Hel-
sinki and Good Clinical Practice guidelines. 
All participants signed a written informed 
consent before study enrollment. This re-
search was registered at the Iranian Registry 
of Clinical Trials (IRCT2017092023861N7). 
 
Participants  
Eighty-eight women with unilateral arm 
lymphedema diagnosed by a lymph therapist 
were recruited to the study at Seyed Khandan 
Rehabilitation Clinic at Tehran, Iran from Oc-
tober 2017 to November 2018. Inclusion cri-
teria were age between 18 and 65 years, BMI 
25 - 40 kg/m2, stage 1 or 2 of lymphedema, 
completed surgery and adjuvant treatment 
completion (except hormone therapy/aroma-
tase inhibitors) at least six months before en-
rollment. Patients with a history of probiotic 
supplements or anti-inflammatory drugs con-
sumption and participating in weight loss pro-
grams in the last 6 months, were excluded 
from the study. Other exclusion criteria were 
included BC recurrence or metastasis, infec-
tion, smoking and alcohol consumption, auto-
immune diseases, serious food allergies, men-
tal illness, endocrine diseases including thy-
roid disorders, diabetes, gastrointestinal prob-
lems, taking multivitamin-mineral and 
omega-3 up to one month before the start of 
the study, continuous and heavy physical ac-
tivity and history of diseases leading to edema 
such as heart, kidney, or liver failure. 
 
Randomization and allocation 
Participants were randomly assigned to 
the synbiotic supplementation group (n=44) 
or the placebo group (n=44). All participants 
received a low-calorie diet from the beginning 
to the end of the intervention. 
For randomization, permuted-block ran-
domization with a block size of 4 was per-
formed by the statistician consultant using the 
online site (www.sealedenvelope.com). To 
apply the concealment in the randomization 
process, unique codes were assigned to the 
supplement boxes, which were generated by 
the software. Randomization and allocation 
were concealed from investigators, partici-
pants, and analyzers until the statistical anal-
ysis was completed. 
 
Weight-reduction program 
In this study, the individual dietary pro-
gram was based on baseline weight and the 
subject’s food records to produce an energy 
deficit of 500 to 1000 kcal/day from estimated 
energy requirements throughout the study. No 
participant was recommended a daily intake 
<1200 kcal. The participant’s energy require-
ment was calculated according to the Mifflin-
St. Jeor equations. The recommended compo-
sition of the diet was 55 % to 60 % of the en-
ergy from carbohydrates, 10 % to 15 % from 
protein and 20 % to 35 % from total fat. 
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Intervention 
The synbiotic supplements (Lacto Care, 
Zist Takhmir Co., Tehran, Iran) contained 109 
colony-forming units (CFU) per gr (CFU/g) 
beneficial bacteria such as Lactobacillus ca-
sei, Lactobacillus acidophilus, Lactobacillus 
rhamnosus, Lactobacillus bulgaricus, 
Bifidobacterium breve, Bifidobacterium 
longum, Streptococcus thermophiles, and 
38.5 mg fructo-oligosaccharides. The placebo 
was a capsule similar in appearance, weight, 
smell, and packaging, containing lactose (Zist 
Takhmir Co., Tehran, Iran). 
The women in the synbiotic or placebo 
groups took a daily capsule for 10 weeks.  
They were asked to keep the study capsules 
refrigerated (between 2 and 7˚ C) throughout 
the study. They were also requested not to 
take any probiotic-containing food, probiotic 
yogurt or its products in 14 days before (2 
week run-in period) and throughout the study. 
Compliance with consumption of capsules 
was monitored once a week through phone 
calls and confirmed by counting the capsules 
in face to face interviews after 5 weeks of in-
tervention. 
 
Assessment of variables 
Demographic and clinical characteristics 
were collected by personal interview and the 
medical report. They were recorded in a 
checklist. Anthropometric indices were meas-
ured for all participants at baseline and after 
10 weeks of intervention. Height and weight 
were measured without shoes and in light 
clothing using a digital scale (Seca, Hamburg, 
Germany). Body mass index (BMI) was cal-
culated using formula weight in kg divided by 
height in m2. Waist circumference was meas-
ured at the narrowest part of the torso.  
Lymphedema volume was measured us-
ing the water displacement method (submerg-
ing the healthy limb and then the affected 
limb in a water tank up to 2 cm below the arm-
pit). Edema volume was calculated as the vol-
ume difference between affected and unaf-
fected arms in milliliters. All measurements 
conducted by an experienced examiner who 
was unaware of the study-group assignments. 
Nutrient intake of the participants at the 
beginning and end of the study, based on a 3-
day food record (two weekdays and one 
weekend day), were calculated by Nutritionist 
IV software (First Databank, San Bruno, 
Calif, USA) modified for Iranian foods. 
Physical activity was assessed using an 
International Physical Activity Questionnaire 
(IPAQ) by interview (Vasheghani-Farahani et 
al., 2011).  
Blood samples were taken after 8-12 hour 
fasting at baseline and the end of the 10 weeks 
intervention. Serum samples were separated 
by centrifugation (Hettich D-78532, 
Tuttlingen, Germany) at 3500 rpm for 10 min 
and stored at -80 °C until assayed. Serum con-
centrations of leptin, IL-1β, and TNF-α were 
measured using ELISA kits (eBioscience, 
US) and hs-CRP was measured by an immu-
noturbidimetric assay (Pars Azmoon kit, Teh-
ran, Iran). 
 
Sample size 
The primary outcome of this study was 
TNF-α, since its effect had not been reported 
in similar studies. Based on the amount of Co-
hen's standard effect, assuming probability of 
a type I error of 5 % (α = 0.05) and a type II 
error of 20 % (β = 0.2; power = 80 %) and the 
Cohen standardized effect value of 0.65 (one 
effect at moderate level), also considering up 
to 10 % losses to follow-up, to detect the de-
sired effect, the sample size was calculated 44 
patients for each group. 
 
Statistical analysis 
For continuous variables, the Shapiro-
Wilk’s test and a histogram were applied to 
ensure normality. All participants who were 
randomly assigned and completed an initial 
assessment were included in the final results 
by using an intention-to-treat analysis. For 
quantitative variables, the mean ± standard 
deviation or the median (first quartile - third 
quartile) and for qualitative variables, fre-
quency (percent) was used. 
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To compare quantitative outcomes be-
tween the study groups, an independent sam-
ples t-test (for age, age at cancer diagnosis, di-
etary intakes, weight, BMI, fat percent, waist 
circumference and physical activity) or a non-
parametric Mann-Whitney test (for time since 
cancer treatment, duration of lymphedema, 
tumor size, CDT course numbers, lymph 
nodes dissected, lymph nodes involved, 
edema volume, hs-CRP, IL-1β, TNF-α, and 
leptin) was used. Changes of outcomes within 
each group after the intervention compared to 
baseline values were assessed by a paired 
sample t-test or a non-parametric Wilcoxon 
rank signed test. Chi-square test or Fisher's 
exact test was used to compare qualitative 
factors (including lymphedema stage, surgery 
type, chemotherapy, radiotherapy, etc.) be-
tween the study groups. Delta (Δ) was used to 
show the differences in the variables before 
and after the intervention. We used AN-
COVA to compare post-intervention out-
comes between the study groups by adjust-
ment on baseline values of each outcome and 
baseline BMI as the covariate. Spearman’s 
rank correlation coefficient analysis was per-
formed to evaluate the relationship between 
changes in body weight/waist circumference 
and the blood factors/edema volume differ-
ence. The level of significance for all statisti-
cal analyses was p < 0.05. All statistical anal-
yses were performed using SPSS version 24 
(IBM SPSS, Armonk, NY: 2016). Non-para-
metric ANCOVA analysis was performed 
with R software (package ‘sm’ in R-3.5.1 for 
windows). 
Our approach for analyses can be consid-
ered as an intention-to-treat (ITT) analysis, 
since it includes every subject who was ran-
domized according to randomized treatment 
assignment. It ignores noncompliance, proto-
col deviations, withdrawal and anything that 
happens after randomization. 
 
RESULTS 
Participants’ characteristics 
As demonstrated in the study flow dia-
gram (Figure 1), we recruited 352 partici-
pants. However, 264 subjects were excluded 
from the study because of not meeting the in-
clusion criteria. Of the 88 women enrolled in 
the study, 44 participants were randomized to 
the synbiotic group, and 44 were randomized 
to the placebo group. Eight participants 
(10 %) withdrew from the study following 
randomization: four patients because of dis-
tance from residence to the clinic, one patient 
because of recurrent disease and three patients 
because of follow-up with other physicians. 
Finally, 41 and 39 participants in the synbiotic 
and placebo groups completed the trial, re-
spectively. 
No side effects were reported following 
the supplementation of synbiotic in breast 
cancer survivors with lymphedema through-
out the study. 
Baseline demographic and clinical char-
acteristics of lymphedema patients have been 
presented in Table 1. The baseline mean (± 
SD) age of participants was 53.80 (± 9.16) 
years in the synbiotic group and 52 (± 7.95) in 
the placebo group. There was no significant 
difference between the two groups regarding 
demographic and clinical characteristics. 
 
Dietary intake 
According to the 3-day food records ob-
tained within each group before and after the 
intervention, there was no statistically signif-
icant difference in terms of energy, dietary 
macro- and micro-nutrient intakes between 
the study groups in baseline and after 10 
weeks of intervention (Table 2).  
However, both synbiotic and placebo 
groups showed a significant within-group re-
duction in daily energy intake (P < 0.001, P < 
0.001), carbohydrate (P < 0.001, P < 0.001), 
protein (P < 0.001, P =0.001), total fat (P = 
0.001, P = 0.005), SFA (P = 0.001, P < 0.001), 
PUFA (P < 0.005, P < 0.001), MUFA (P = 
0.003, P < 0.001), cholesterol (P=0.047, 
P=0.037), sodium (P=0.035, P=0.002) and 
beta-carotene (P=0.049, P=0.001) respec-
tively (Table 2). 
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Figure 1: Consort diagram 
 
 
 
Anthropometry and physical activity  
The mean values of weight (kg), BMI 
(kg/m2), body fat percent ( %), waist circum-
ference (cm) and physical activity (min/week) 
at baseline and after 10 weeks in synbiotic and 
control groups are depicted in Table 3. The 
statistic tests showed no significant difference 
between the study groups after the interven-
tion. Within groups changes showed signifi-
cant statistical differences (P< 0.005) in syn-
biotic and control groups regarding mean 
value of weight (-2.48 ± 3.03 kg, -1.73 ± 2.26 
kg), BMI (-0.95 ± 1.14 kg/m2, -0.68 ± 0.90 
kg/m2), body fat percent (-1.14 % ± 1.37,  
-0.83 % ± 1.09) and waist circumference 
changes (-3.89 ± 3.26 cm, -3.84 ± 3.60 cm), 
respectively.  
The physical activity level significantly 
increased within each group [17.0 (3.25, 
30.50) min/week and 21.0 (7.0, 33.0) 
min/week in synbiotic and control groups re-
spectively, P< 0.001]. The intention-to-treat 
(ITT) analysis did not show different results 
between the study groups. 
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Table 1: Clinical and demographic characteristics of participants at baseline 
 Groups P 
Synbiotic (n=44 ) 
 
Control (n=44 ) 
Mean ± SD    
Age, years 53.80 ± 9.16 52.39 ± 7.95 0.742a 
Age at cancer diagnosis, years 47.98 ± 9.35 48.82 ± 7.76 0.648a
Median (range)    
Time since cancer treatment, years 3 (1,5) 3 (1,4) 0.522b
Duration of lymphedema, months 8 (2.5,24) 11 (3,24)  0.631b
Tumor size, cm 3 (1.85,4) 2.5 (2,4.7) 0.732b
CDT course numbers 15 (14,20) 15 (12,20) 0.515b
Lymph nodes dissected 13 (8.5,17.5) 14 (10,17) 0.719b
Lymph nodes involved 2 (1,4) 3 (1,5) 0.302b
N (%)     
Lymphedema stage I 7 (15.9%) 8 (18.2%) 0.777c
II  37 (84.1%) 36 (81.8%) 
Surgery type Mastectomy 28 (63.6%) 27 (61.4%) 0.826c
Lumpectomy 16 (36.4%) 17 (38.6%) 
Chemotherapy Yes 42 (95.5%) 42 (95.5%) 0.999c
No 2 (4.5%) 2 (4.5%) 
Radiotherapy Yes 44 (100%) 40 (90.9%) 0.116c
No 0 4 (%9.1) 
Breast cancer stage at  
diagnosis 
I  4 (9.1%) 4 (9.1%) 0.934c
II 34 (77.3%) 32 (72.7%) 
III 6 (13.6%) 8 (18.2%) 
Estrogen status Positive 33 (75%) 36 (81.8%) 0.437c
Negative  11 (25%) 8 (18.2%) 
Progesterone status Positive 34 (77.3%) 32 (72.7%) 0.622c
Negative 10 (22.7%) 12 (27.3%) 
HER2 status Positive 9 (20.5%) 7 (15.9%) 0.580c
Negative 35 (79.5%) 37 (84.1%) 
Endocrine therapy 
 
Tamoxifen  34 (77.3%) 28 (63.6%) 0.161c
0.135c Aromatase  
inhibitors 
19 (43.2%) 26 (59.1%) 
Herceptin Yes 9 (20.5%) 7 (15.9%) 0.580c
No 35 (79.5%) 37 (84.1%) 
Homogeneity of hands Yes 20 (45.5%) 25 (58.8%) 0.286c
No 24 (54.5%) 19 (43.2%) 
Occupation Full-time 10 (22.71%) 13 (29.5%) 0.467c 
 Homemaker 34 (77.32%) 31 (70.5%)  
Marital status Married 39 (88.61%) 40 (90.9%)  0.999c 
 Other  5 (11.40%) 4 (9.10%)  
Education University 11 (25%) 11 (25%) 0.656c 
 High school 22 (50%) 26 (59.1%)  
 Elementary 8 (18.21%) 4 (9.1%)  
 Illiterate 3 (6.80%) 3 (6.80%)  
a Independent-Samples t-test. b Mann–Whitney U test. c chi-square or Fisher exact test. 
Parametric quantitative data reported as mean ± SD, non-parametric quantitative data reported as me-
dian (Q1, Q3), qualitative data reported as number (%). 
CDT, Complete decongestive therapy; TAC, Taxotere, Adriamycin and Cyclophosphamide; Tax, Taxol; 
AC, Adriamycin and Cyclophosphamide; HER2, human epidermal growth factor receptor 2. 
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Table 2: Dietary intakes of participants throughout the study 
  Groups P 
Synbiotic (n=44 ) Control (n=44 ) 
Energy 
(kcal/d) 
Before  2941.81 ± 349.09 3013.97 ± 329.68 0.322a
After 2537.39 ± 429.39 2562.89 ± 468.33 0.800a
P b < 0.001 < 0.001  
Carbohy-
drate (gr/d) 
 
Before  348.84 ± 57.99 349.81 ± 75.23 0.946a
After 308.82 ± 54.29 325.67 ± 58.73 0.186a
P b < 0.001 < 0.001  
Total fiber 
(gr/d) 
Before  26.10 ± 10.51 27.90 ± 9.89 0.470a 
After 27.43 ± 10.04 29.01 ± 9.74 0.418a 
P b 0.192 0.063  
Protein (gr/d) 
 
Before  118.66 ± 37.77 132.63 ± 45.54 0.121a
After 100.08 ± 21.35 110.88 ± 44.03 0.164a
P b < 0.001 0.001  
Total fat 
(gr/d) 
Before  135.73±  204.20 143.15 ± 103.90 0.289a
After 124.41±  52.68 122.50 ± 85.74 0.709a
P b 0.001 0.005  
SAFA (mg/d) Before  26.97 ± 8.60 27.50 ± 7.84 0.762a
After 21.44 ± 22.43 22.37 ± 8.33 0.290a
P b 0.001 < 0.001  
PUFA (mg/d) Before  52.07 ± 21.90 54.06 ± 21.07 0.387a
After 49.84 ± 35.05 42.38 ± 22.56 0.309a
P b 0.005 < 0.001  
MUFA (mg/d) 
  
Before  22.82 ± 8.29 32.17 ± 7.85 0.176a
After 29.26 ± 40.12 25.81 ± 10.62 0.335a
 P b 0.003 < 0.001  
Cholesterol 
(mg/d) 
 
Before  429.22 ± 174.54 458.60 ± 190.98 0.453a
After 368.85 ± 120.75 376.60 ± 123.21 0.777a
P b 0.047 0.037  
Magnesium 
(mg/d) 
Before  386.10 ± 115.18 408.77 ± 111.30 0.351a
After 355.90 ± 106.05 441.90 ± 301.89 0.090a
P b 0.340 0.460  
Calcium 
(mg/d) 
Before  1182.61 ± 431.36 1332.29 ± 859.13 0.305a
After 1165.73 ± 445.55 1140.79 ± 365.04 0.785a
P b 0.486 0.151  
Sodium 
(mg/d) 
Before  1627.44 ± 793.14 1430.79 ± 509.92 0.171a
After 1523.15 ± 815.81 1379.86 ± 490.69 0.173a
P b 0.035 0.002  
Potassium 
(mg/d) 
Before  4828.65 ± 1728.52 5240.36 ±  1710.64 0.265a
After 4561.09 ± 1626.52 4986.15 ± 1572.50 0.239a
P b 0.242 0.260  
Vitamin E 
(mg/d) 
Before  4.90 ± 1.83 5.49 ± 2.21 0.176a
After 4.33 ± 1.73 5.07 ± 2.06 0.084a
P b 0.110 0.100  
Vitamin C 
(mg/d) 
Before  149.60 ± 86.02 184.08 ± 82.24 0.058a
After 143.42 ± 85.69 162.70 ± 89.46 0.328a
P b 0.874 0.090  
β-Carotene 
(mg/d) 
Before  420.31 ± 641.47 593.22 ± 709.46 0.234a
After 446.74 ± 687.54 543.23 ± 760.49 0.553a
 P b 0.049 0.001  
a Independent-Samples t-test. b Paired sample t-test. 
Parametric quantitative data reported as mean ± SD 
SAFA, saturated fatty acids; PUFA, Polyunsaturated fatty acids; MUFA, Monounsaturated fatty acids. 
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Table 3: Anthropometrics and physical activity characteristics in two groups before and after intervention 
  
 
 
Groups  P Adjusted 
P * 
Synbiotic (n=44 ) Control (n=44 )  
Weight (kg) 
 
Before  79.72 ± 11.86 78.23 ± 12.43 0.565a  
After 77.99 ± 11.52 77.07 ± 12.76 0.738a 0.256 
% change - 3.11 - 2.21 0.212a  
P c <0.001 <0.001   
BMI (kg/m2) Before  30.93 ± 3.84 30.88 ± 3.81 0.956a  
After 30.32 ± 3.68 30.53 ± 3.79 0.800a 0.245 
% change - 3.07 - 2.20 0.246a  
P c <0.001 <0.001   
Fat percent 
(%)  
Before  43.95 ± 4.99 43.92 ± 5.02 0.976a  
After 43.41 ± 4.42 43.43 ± 5.06 0.986a 0.263 
% change - 2.59 - 1.88 0.260a  
P c <0.001 <0.001   
 
waist cir-
cumference 
(cm) 
Before  104.10 ± 7.80 105.11 ± 8.42 0.561a  
After 100.39 ± 7.93 101.53 ± 8.51 0.534a 0.841 
% change - 3.73 - 3.65 0.954a  
P c 0.005 0.003   
Physical 
activity 
(min/week) 
Before  376.15 ± 192.59 339.89 ± 176.88 0.360a  
After 538.68 ± 686.12 366.43 ± 182.15 0.128a 0.195 
% change 43.08 7.96 0.450b  
P d <0.001 <0.001   
a Independent-Samples t-test. b Mann–Whitney U test. c Paired sample t-test. d Wilcoxon signed-rank 
test. *ANCOVA test adjusted for baseline measures of each variable and baseline BMI. 
Parametric quantitative data reported as mean ± SD 
BMI, Body Mass Index 
 
 
Edema volume measurement 
As shown in Table 4, there was a signifi-
cant reduction in edema volume in the synbi-
otic group after the 10 week intervention  
(-37.26 percent, P< 0.001). However, accord-
ing to the ANCOVA tests adjusted for base-
line edema volume and pre-intervention BMI, 
there were no significant differences between 
the study groups after the intervention 
(P=0.180). 
 
Inflammatory markers  
Baseline measures of inflammatory mark-
ers were not significantly different between 
the study groups, except hs-CRP [median 
(IQR): 3.20 (3.75), 1.85 (1.88) in synbiotic 
and placebo group respectively, P= 0.022]. In 
the synbiotic group after 10 weeks of inter-
vention, hs-CRP (-3.12 percent, P=0.032), IL-
1β (-8.37 percent, P=0.018), and leptin  
(-25.58 percent, P=0.026) decreased signifi-
cantly (Table 4). Initial analysis showed no 
significant change in serum TNF-α levels fol-
lowing supplementation with synbiotic (Ta-
ble 5) but ITT analysis revealed lower TNF-α 
values in the synbiotic group following inter-
vention (P=0.039). Data in Table 5 demon-
strates that 10 weeks of synbiotic supplemen-
tation significantly reduced TNF-α and leptin 
between the study groups (Adjusted P= 0.039; 
P= 0.003, respectively). 
The correlation of changes in serum hs-
CRP with body weight (r=0.420, P=0.006) 
and waist circumference (r=0.376, P=0.018) 
alterations in the synbiotic group was statisti-
cally significant. Also, edema volume 
changes significantly correlated with body 
weight (r=0.326, P=0.038) and waist circum-
ference (r= 0.330, P=0.035) in the synbiotic 
group (Table 6).
Table 4: Participants edema volume characteristics in two groups before and after intervention 
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Groups  P Adjusted 
P * 
Synbiotic (n=44 ) Control (n=44 )  
Edema  
volume 
(mm3) 
Before  400.0 (555) 400.0 (480) 0.380b  
After 320.0 (440) 400.0 (600) 0.847b 0.180 
% change - 37.26 - 20.75 0.209a  
P c <0.001 0.061   
a Independent-Samples t-test. b Mann–Whitney U test. c Wilcoxon signed-rank test. *ANCOVA test ad-
justed for baseline edema volume and baseline BMI. 
Edema volume reported as median (IQR). 
 
 
Table 5: Inflammatory markers in two groups before and after intervention 
  Groups P 
 
Adjusted 
P * 
Synbiotic (n=44 ) Control (n=44 )  
hs-CRP 
(mg/L) 
Before  3.20 (3.75) 1.85 (1.88) 0.022b 0.550 
After 3.10 (2.65) 1.80 (2.3) 0.085b 
% change - 3.12 - 2.70 0.021a 
P c 0.032 0.526  
IL-1β 
(pgL) 
Before  382.0 (890.75) 339.0 (128) 0.140b 0.118 
After 350.0 (816) 337.0 (285.5) 0.348b 
% change - 8.37 - 5.01 0.528a 
P c 0.018 0.030  
TNF-α 
(ng/L)  
Before  36.0 (19.5) 38.0 (107.75) 0.187b 0.039 
After 34.0 (18.5) 40.0 (120) 0.058b 
% change - 5.55 5.26 0.097a 
P c 0.124 0.377  
Leptin 
(ng/ml) 
Before  86.0 (32) 105.0 (202.5) 0.411b 0.003 
After 64.0 (32.5) 73.0 (218) 0.004b 
% change - 25.58 -20.47 0.071a 
P c 0.026 0.523  
a Independent-Samples t-test. b Mann–Whitney U test. c Wilcoxon signed-rank test. * ANCOVA test ad-
justed for baseline inflammatory markers and baseline BMI. 
Non-parametric quantitative data reported as median (IQR). 
hs-CRP, high-sensitivity C-reactive protein; IL-1, Interleukin-1; TNF-α, Tumor Necrosis Factor-α. 
 
 
 
DISCUSSION 
This is the first interventional trial that in-
vestigates the possible beneficial role of syn-
biotic supplementation on inflammatory 
markers (TNF-α, IL-1β, hs-CRP), serum lep-
tin concentration, anthropometric parameters, 
and edema volume in BCRL patients.  
Our results revealed that synbiotic supple-
mentation for 10 weeks reduced edema vol-
ume, the serum concentration of hs-CRP, IL-
1β and leptin in overweight and obese patients 
with BCRL. Furthermore, the synbiotics 
group had significantly lower levels of serum 
leptin and TNF-α concentration compared to 
placebo after the intervention. 
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Table 6: The correlation of inflammatory marker and edema volume with body weight and waist circum-
ference in synbiotic and control groups  
 
 
 Synbiotic 
(n=44) 
Control 
(n=44) 
 ∆	Body 
weight 
(Kg) 
∆ Waist  
circumference 
(cm) 
∆ Body 
weight 
(Kg) 
∆	Waist  
circumference 
(cm) 
∆ hs-CRP 
(mg/L) 
r 
P 
0.420 
0.006 
0.376 
0.018 
0.178 
0.279 
0.189 
  0.236 
∆ IL-1β 
(pg/L) 
r 
P 
-0.084 
0.600 
-0.169 
0.290 
0.261 
0.108 
0.241 
0.140 
∆ TNF-α 
(ng/L) 
r 
P 
-0.072 
0.656 
-0.161 
0.315 
0.207 
0.207 
0.027 
0.868 
∆ Leptin 
(ng/ml) 
r 
P 
-0.112 
0.485 
0.159 
0.320 
-0.011 
0.946 
-0.209 
0.202 
∆ Edema  
volume (mm3) 
r 
P 
0.326 
0.038 
0.330 
0.035 
0.109 
0.509 
0.039 
0.815 
Significant correlations (P < 0.05) are shown in bold text. 
Data from the two groups were pooled before analysis. 
∆ Indicates change from baseline. 
hs-CRP, high-sensitivity C-reactive protein; IL-1β, Interleukin-1; TNF-α, Tumor Necrosis Factor-α. 
 
 
 
A significant improvement was seen in 
anthropometric indices including body 
weight, BMI, fat percent and waist circumfer-
ence within groups at the end of the interven-
tion which is the predictable consequence of 
the low-calorie diet prescribed to all patients. 
The anthropometric changes were not signifi-
cant between the study groups because the 
simultaneous occurrence of cancer, 
lymphedema and obesity increased the pa-
tient’s inflammation (Kolb et al., 2016, Zahid 
et al., 2016) to the level that we could not ob-
serve any significant effects for synbiotics in 
these cases. Also, in a meta-analysis study 
was shown that probiotic supplementation (3 
to 12 weeks) has a small size effect on the re-
duction of anthropometric factors (Borgeraas 
et al., 2018). 
Reduction in excess edema volume after 
synbiotic supplementation is a new finding 
that has not been reported elsewhere. The per-
centage of edema reduction was 37.36 % and 
20.75 % in the synbiotic and placebo groups, 
respectively. The lack of significant differ-
ences between the study groups after the in-
tervention could indicate the positive effects 
of the weight-loss diet on this marker. In the 
study by Shaw et al. 12 weeks prescription of 
a weight-loss diet, led to a significant reduc-
tion in weight, BMI, and edema volume in 
BCRL patients (Shaw et al., 2007a) Probiot-
ics with their weight-lowering characteristics 
can promote this positive effect. Obesity is 
one of the well-known factors in the onset and 
progression of lymphedema and obese indi-
viduals have a decreased lymphatic transport 
capacity (Yoon et al., 2018; Savetsky et al., 
2014).  
In different studies, the prognostic effect 
of high BMI in lymphedema incidence (Yoon 
et al., 2018; Iyigun et al., 2018; Helyer et al., 
2010) and the predictive effect of weight loss 
accompanied by complete decongestive ther-
apy in edema reduction (Shaw et al., 2007a, 
b; Duyur Cakit et al., 2019) have been con-
firmed.  
Alleviated hs-CRP serum levels in the 
synbiotic group was another finding of this 
study. This beneficial effect was also seen in 
another study performed on diabetic hemodi-
alysis patients. After 12 weeks of interven-
tion, serum hs-CRP was significantly lower in 
the synbiotics group (Soleimani et al., 2017). 
Obesity by activation of the c-Jun N-terminal 
kinase, nuclear factor-kappa B, and protein 
kinase R pathways induce the inflammatory 
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response (Solinas et al., 2010; Nakamura et 
al., 2010). Lack of significant differences in 
hs-CRP serum levels between the study 
groups after the intervention may be because 
of the synergistic effects of cancer/chemo-
therapy and obesity on inflammation in our 
study (Kolb et al., 2016; Zahid et al., 2016). 
The results of the current study showed a 
significant reduction in serum IL-1β in both 
groups after the intervention (-8.37 %; control 
= -5.01 %), but the non-significant differ-
ences of this variable between groups are 
probably due to the beneficial effects of the 
weight loss program on this cytokine, owing 
to the fact that a decrease in body fat during 
weight loss reduces the production of IL-1β 
(Kirchner et al., 2014). Shadnoush et al. re-
ported that 8 weeks of consumption of 
bifidobacterium and lactobacillus in the form 
of probiotic yogurt, decreased serum IL-1β 
concentration in inflammatory bowel disease 
patients compared to control (Shadnoush et 
al., 2013). No weight loss program was per-
formed in their study that could explain why 
the differences in serum IL-1β were signifi-
cant after probiotic intake.  
Obesity leads to impairment and imbal-
ance in gut microbiota called dysbiosis which 
weakens intestinal integrity accompanied by 
lipopolysaccharide (LPS)-related endotoxe-
mia. LPS is a large molecule that exists in the 
cell wall of gram-negative bacteria. LPS stim-
ulates the activation of the transcription nu-
clear factor-kappa B (NF-κB) by binding to 
toll-like receptor 4 (TLR4) in intestinal epi-
thelial cells. NF-κB upregulates gene expres-
sion of pro-inflammatory cytokines such as 
TNF-α, IL-1β, and IL-6 which mediate a rise 
in hs-CRP, inflammation, and consequently 
edema (Neyrinck et al., 2016; Torres et al., 
2018; Dinarello, 2009). Also, producing 
short-chain fatty acids by probiotics prevents 
the synthesis of hepatic CRP that results in a 
reduction in its serum levels (Badehnoosh et 
al., 2018).  
We demonstrated that synbiotic supple-
mentation for 10 weeks in BCRL patients led 
to a significant reduction in serum leptin lev-
els compared to baseline and control group. 
This effect was also seen in studies on over-
weight and obese individuals (Sanchez et al., 
2014; Zarrati et al., 2014), but it was not in 
line with the study by Mobini et al. Supple-
mentation with Lactobacillus reuteri in dia-
betic patients for 12 weeks, could not change 
leptin (Mobini et al., 2017). Our supplements 
contain diverse strains of probiotics compared 
to that study. Each strain of probiotics may 
exert a special function (Pandey et al., 2015), 
which may be responsible for the incon-
sistency of the results. Several mechanisms 
can explain the beneficial effects of probiotics 
serum leptin levels. Probiotics have a critical 
role in leptin secretion regulation (Behrouz et 
al., 2017). Leptin increases the production of 
TNF-α in monocytes (Scarpellini and Tack, 
2012; Zhou et al., 2011). Any factor that re-
duces the leptin level can also reduce the lev-
els of TNF-α. Therefore, in our study, a de-
crease in the leptin serum level consequently 
reduced the TNF-α serum level in the synbi-
otic group compared with the placebo. De-
spite a significant decrease in TNF-α serum 
level, because of multiple outcomes and the 
possibility of significant correlation due to 
multiple testing, this factor should be inter-
preted with caution. An adjusted significant 
level can be confirmed in the next and larger 
studies. 
In spite of the potential strengths of our 
study, such as using a probiotic intervention 
for the first time among BCRL patients, this 
study has some limitations. Although the syn-
biotics supplementation may affect fecal bac-
terial load, we could not assess this correla-
tion because of budget limitations. Also, we 
did not consider a control group receiving placebo 
capsules without any low-calorie diet. So, we can 
not conclude if the weight reduction program had 
a synergistic effect along with the synbiotic cap-
sules or not. Evaluation of the gene expression 
of inflammatory cytokines in future re-
searches may provide valuable evidence in 
this field.  
 
EXCLI Journal 2020;19:1-15 – ISSN 1611-2156 
Received: October 11, 2019, accepted: December 18, 2019, published: January 02, 2020 
 
 
13 
CONCLUSION 
In conclusion, 10 weeks of synbiotic sup-
plementation along with an LCD program 
among BCRL patients resulted in a significant 
reduction in serum levels of TNF-α and leptin 
compared with the control group. Also, 
edema volume was significantly reduced 
within the synbiotic group after intervention. 
However, no significant differences were 
found in either of the anthropometric varia-
bles, IL-1β, and hs-CRP between the study 
groups. Weight reduction and synbiotic prod-
uct consumption in the daily diet of 
lymphedema patients may be suggested as ef-
fective and safe interventions in lymphedema 
management. 
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